

Matthew Dankner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9512476/publications.pdf>

Version: 2024-02-01

17
papers

620
citations

1040056

9
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1169
citing authors

#	ARTICLE	IF	CITATIONS
1	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. <i>Cell Reports</i> , 2022, 39, 110634.	6.4	10
2	Spatially mapping the immune landscape of melanoma using imaging mass cytometry. <i>Science Immunology</i> , 2022, 7, eabi5072.	11.9	60
3	The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers. <i>Cancers</i> , 2021, 13, 732.	3.7	14
4	The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes. <i>Neuro-Oncology</i> , 2021, 23, 1207-1207.	1.2	1
5	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021, 12, 3299.	12.8	24
6	Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 1470-1480.	1.2	18
7	Post-mortem tissue donation programs as platforms to accelerate cancer research. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 163-170.	3.0	4
8	An exercise in scientific writing for physicians in training. <i>Clinical and Investigative Medicine</i> , 2020, 43, E35-E38.	0.6	2
9	CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. <i>American Journal of Pathology</i> , 2019, 189, 1451-1461.	3.8	9
10	BRAF Mutation Class and Clinical Outcomes Letter. <i>Clinical Cancer Research</i> , 2019, 25, 3188-3188.	7.0	1
11	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. <i>Oncogene</i> , 2018, 37, 3183-3199.	5.9	317
12	Comment on "Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study"™. <i>British Journal of Cancer</i> , 2018, 118, 1276-1277.	6.4	2
13	Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	3.0	10
14	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. <i>Anti-Cancer Drugs</i> , 2018, 29, 774-785.	1.4	12
15	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. <i>Clinical Cancer Research</i> , 2018, 24, 6483-6494.	7.0	55
16	Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations. , 2018, , .		1
17	CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy. <i>OncolImmunology</i> , 2017, 6, 00-00.	4.6	79